Medifast (MED) Earnings Date & Reports

Key Takeaways

• Medifast reported third-quarter 2026 revenue of $72.05 million, down 19.4% year over year, but slightly above analyst consensus of $71.3 million.
• The company posted a GAAP net loss of $17.51 million, or $1.57 per share, versus a $2.26 million loss a year earlier, as restructuring charges weighed on results.
• Adjusted (non-GAAP) net loss narrowed to $2.1 million, or $0.19 per share, reflecting the company's Catalyst cost-reduction program.
• Management guided to a return to profitability in the fourth quarter, with EPS expected between $0.00 and $0.25.
• Active earning coaches fell 47.7% year over year to 10,200, though revenue per coach rose 54.1% to $7,064.
• Medifast ended the quarter with roughly $172.5 million in cash and investments and no debt.
• For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated analysis pages.
• Discover automated trading strategies by exploring Trending AI Robots.

Earnings Context and Why It Matters

Medifast is in the midst of a strategic pivot from a traditional weight-management business toward a broader metabolic-health platform built around its Trilivy brand and MetaVantage technology. The third quarter represents a key checkpoint on that transformation, as the company completed major launches and executed most of its Catalyst restructuring program. Investors are watching closely to see whether revenue, which has stabilized near $75 million for four consecutive quarters, can transition into renewed growth, and whether the leaner cost base can deliver a return to profitability. The results also carry significance for the wider wellness and GLP-1 (glucagon-like peptide-1) weight-loss market, where Medifast is positioning coaching and nutrition as a complement to medications rather than a competitor.

Reported Results

For the third quarter ended September 30, 2026, Medifast reported revenue of $72.05 million, a 19.4% decline from $89.41 million in the prior-year period but modestly above consensus estimates of $71.3 million. The decline was driven primarily by a reduction in the number of active earning coaches, which fell 47.7% year over year to 10,200.

The company recorded a GAAP (Generally Accepted Accounting Principles) net loss of $17.51 million, or $1.57 per share, compared with a loss of $2.26 million, or $0.21 per share, in the same quarter last year. The wider loss reflected approximately $13.8 million in Catalyst restructuring charges within selling, general, and administrative expenses. On an adjusted, non-GAAP basis, the net loss was $2.1 million, or $0.19 per share, better than some analyst expectations. Operating loss widened to $19.4 million from $4.1 million a year earlier.

Looking ahead, Medifast guided fourth-quarter revenue to a range of $55 million to $75 million and EPS between $0.00 and $0.25, signaling an expected return to profitability. For the full year, the company projects revenue of $280 million to $300 million and a loss per share of $1.80 to $2.05.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking Medifast and similar wellness names, the AI Screener offers a practical starting point for broader market research.

Market Reaction and Investor Sentiment

Medifast shares moved higher in early trading following the release, as investors weighed a narrower adjusted loss and stronger-than-expected fourth-quarter profitability guidance against the wider GAAP loss. The forward-looking signal — management's expectation of returning to profitability in the fourth quarter — appeared to resonate with the market, particularly given the company's debt-free balance sheet and its roughly $172.5 million cash position.

Sentiment remains cautious, however. The continued decline in active earning coaches and the year-over-year revenue contraction underscore that Medifast's turnaround is still in its early stages. Investors are closely monitoring whether the new Trilivy brand, MetaVantage products, and revised coach compensation plan can stabilize the coach base and eventually reignite growth.

Forward Outlook and Key Factors to Monitor

The most important near-term catalyst is whether Medifast delivers on its stated goal of returning to profitability in the fourth quarter. Management's guidance of breakeven-to-positive EPS, alongside adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of $2 million to $6 million, will be a key test of the Catalyst cost program's effectiveness.

Investors should also watch the trajectory of active earning coaches. While revenue per coach has improved for four consecutive quarters, the declining coach count remains the primary headwind to revenue growth. Stabilizing this metric is essential for a durable turnaround.

On the product side, early adoption of the new Trilivy Reset Fuelings has been encouraging, with management reporting that 95% of active earning coaches offered the line by September. The full conversion of product SKUs to the new Reset formulation by the end of the fourth quarter could influence both client retention and margin trends.

Finally, the broader metabolic-health landscape — including competition from GLP-1 medications and evolving consumer preferences — will shape Medifast's ability to differentiate its coaching-led, nutrition-focused approach. The company's positioning as a complement to medication-based weight loss, rather than a direct competitor, is a strategic theme worth monitoring in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations